Health
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet
This first-in-human trial shows that a subunit vaccine comprising mammalian cell culture-derived,MF59-adjuvanted, molecular clamp-stabilised recombinant spike protein…
We use cookies to help provide and enhance our service and tailor content and ads. To update your cookie settings, please visit the Cookie Preference Center for this site.Copyright © 2021 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.
Privacy Policy Terms and Conditions
-
Noosa News19 hours agoDangerous storm pounds south-east Queensland with giant hail, blackouts and widespread damage
-
Noosa News22 hours agoBruce Highway fatal: Grandmother’s heartbreak as daughter and granddaughter killed in Queensland truck crash
-
General6 hours agoVictorian government blocked fire service from pursuing US giant over PFAS contamination
-
Business22 hours agoWhy Gentrack, Monash IVF, Pro Medicus, and Qube shares are racing higher today